Clinical efficacy observation of Lingbao Huxindan in treatment of primary microvascular angina pectoris
Objective To observe and study the clinical efficacy and safety of Lingbao Huxindan in the treatment of primary microvascular angina pectoris.Methods Patients(76 cases)with primary microvascular angina pectoris in Nanyang Central Hospital from December 2019 to June 2022 were divided into control(38 cases)and treatment(38 cases)group according to random number table method.Patients in the control group were administered with routine treatment for secondary prevention of coronary atherosclerotic heart disease.Patients in the treatment group were po administered with Lingbao Huxindan on the basis of the control group,4 grains/time,three times daily.Patients in two groups were treated for 4 weeks.After treatment,the clinical evaluations were evaluated,the SAQ scores,exercise treadmill results,and CFR in two groups before and after treatment were compared.Results After treatment,the clinical effective rate of the treatment group was 92.11%,which was significantly higher than that of the control group(71.05%,P<0.05).After treatment,the SAQ score of the two groups was higher than that before treatment(P<0.05),and which of the treatment group was significantly higher than that of the control group(P<0.05).After treatment,the total exercise time of treadmill was significantly increased,while the maximum depression of ST was significantly decreased in both groups(P<0.05),and the improvement of treadmill results in the treatment group was significantly better than that in the control group(P<0.05).After treatment,the CFR index in two groups was significantly higher than that before treatment(P<0.05),and the coronary flow reserve in the treatment group was significantly higher than that in the control group(P<0.05).Conclusion Lingbao Huxindan can improve the clinical symptoms of patients with microvascular angina pectoris,increase coronary blood flow reserve,enhance exercise tolerance and improve the quality of life of patients.
NETL
NSTL
万方数据
